Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verdecchia, A.
Right arrow Articles by Paci, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verdecchia, A.
Right arrow Articles by Paci, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1128-1139, 2002
© 2002 European Society for Medical Oncology


Original Paper

A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain

A. Verdecchia1,+, A. Micheli2, M. Colonna3, V. Moreno4, M. I. Izarzugaza5 and E. Paci6

1 Istituto Superiore di Sanità, Rome; 2 Istituto Nazionale Tumori, Milan, Italy; 3 Registre de Tumeur d’Isère, Grenoble, France; 4 Institut Catala d’Oncologia, Barcelona; 5 Registro de Cancer de Euskadi, Bilbao, Spain; 6 Registro Tumori Toscano, Florence, Italy

Received 18 June 2001; revised 17 December 2001; accepted 9 January 2002

A comparative analysis of cancer prevalence in France, Spain and Italy is presented as part of the EUROPREVAL project. The three countries are culturally and sociologically relatively homogeneous compared with Europe as a whole. However, in all three countries, the cancer registries (CRs) providing the data for prevalence calculation cover only small fractions of the populations, and have been operating for relatively short periods. This leads to problems of representativity and to prevalence underestimates as surviving cases diagnosed before operation of the CR are not recorded.

Partial prevalences obtained directly from CR data were therefore corrected using a completeness index obtained by modelling to provide estimates of the complete prevalence. For CRs operating for only 5 years, only approximately half the prevalence was observed. Thus, due to the rather recent start of most of southern European CRs, the role of correction is very important.

The prevalence of all cancers was highest in Italy for women and in France for men, while lowest in Spain. Differences in the age structures of the populations were the major cause of these discrepancies and after age adjustment only the prevalence of stomach cancer remained highest in Italy, although differences in incidence also contributed to the prevalence differences. Survival varied little between the three countries and differences in incidence are more important determinants of prevalence. Prevalence of cancer in the elderly represents an increasing load for the community, particularly for France, Italy and Spain due to the ageing population in these countries.

Elderly patients with cancer frequently suffer from problems of co-morbidity and disability factors, thus placing a burden on the local medical system where this proportion is high. Prevalent cases diagnosed 1–5 years before the prevalence date formed approximately one-third of the total prevalence, with higher proportions for melanoma, and prostate cancer in males and breast and colorectal cancer in females, and lower proportions for uterine cancer. This subset of the prevalent population consists of those probably on intensive follow-up, or being treated for cancer recurrence or sequelae to primary therapy.

Key words: cancer, France, Italy, prevalence, Spain


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. F. Kerstann, P. T. Bradford, R. Steighner, D. Calista, M. C. Fargnoli, K. Peris, M. C. Scaini, C. Menin, P. Ghiorzo, G. Bianchi-Scarra', et al.
No Evidence for Linkage with Melanoma in Italian Melanoma-Prone Families
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1838 - 1840.
[Full Text] [PDF]


Home page
J. Med. Genet.Home page
M T Landi, A M Goldstein, S Tsang, D Munroe, W Modi, M Ter-Minassian, R Steighner, M Dean, N Metheny, B Staats, et al.
Genetic susceptibility in familial melanoma from northeastern Italy
J. Med. Genet., July 1, 2004; 41(7): 557 - 566.
[Full Text] [PDF]


Home page
Ann OncolHome page
T. Moller, H. Anderson, T. Aareleid, T. Hakulinen, H. Storm, L. Tryggvadottir, I. Corazziari, and E. Mugno
Cancer prevalence in Northern Europe: the EUROPREVAL study
Ann. Onc., June 1, 2003; 14(6): 946 - 957.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.